WO2001053284A1 - Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram - Google Patents

Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram Download PDF

Info

Publication number
WO2001053284A1
WO2001053284A1 PCT/EP2001/000617 EP0100617W WO0153284A1 WO 2001053284 A1 WO2001053284 A1 WO 2001053284A1 EP 0100617 W EP0100617 W EP 0100617W WO 0153284 A1 WO0153284 A1 WO 0153284A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
carboxyphthalide
acid
mixture
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/000617
Other languages
English (en)
French (fr)
Inventor
Leone Dall'asta
Umberto Casazza
Giovani Cotticelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infosint SA
Norpharma SpA
Original Assignee
Infosint SA
Norpharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26332721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001053284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ROA200200989A priority Critical patent/RO121737B1/ro
Priority to PL01356563A priority patent/PL356563A1/xx
Priority to HU0204187A priority patent/HUP0204187A3/hu
Priority to BR0107853-4A priority patent/BR0107853A/pt
Priority to EP01901181A priority patent/EP1187822A1/en
Application filed by Infosint SA, Norpharma SpA filed Critical Infosint SA
Priority to MXPA02007031A priority patent/MXPA02007031A/es
Priority to CA2397497A priority patent/CA2397497C/en
Priority to AU26798/01A priority patent/AU779581B2/en
Publication of WO2001053284A1 publication Critical patent/WO2001053284A1/en
Priority to BG106925A priority patent/BG65763B1/bg
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Definitions

  • the present invention concerns a process for the preparation of an isobenzofuran derivative. More particularly, the invention refers to a process for the preparation of 1-oxo-l, 3-dihydro-5- 5 isobenzofurancarboxylic acid.
  • 5- 15 carboxyphthalide is an intermediate useful in the synthesis of citalopram, a well-known antidepressant drug, whose preparation using said intermediate is described in the International Patent Application WO 00023431 and in the corresponding Italian Patent Application IT1999 MI 0001724, whose contents must be considered 20 as integral part of the present description.
  • 5-carboxyphthalide may be prepared by reduction of one of the carbonyl groups of trimellitic anhydride, which can occur by hydrogenation or, according to DE-2630927, by electrochemical reduction.
  • This method has the drawback of giving 25 a 5-carboxyphthalide containing, as a by-product, the 6 isomer in an amount which can reach 10%.
  • An impurity which is present in such a percent cannot be accepted if 5-carboxyphthalide must be used as an intermediate in the preparation of drugs and, in such a case, it must be removed or strongly reduced to a value not higher 30 than 0.1%. The removal of the 6 isomer occurs by several crystallizations which lower the yield in final product considerably .
  • 5-carboxyphthalide may be prepared according to another method, described in US 3,607,884, which
  • the present invention provides, according to a method of simple execution, a process for the preparation of 5- carboxyphthalide of formula A, which comprises adding terephthalic acid of formula I
  • formaldehyde is used in one of its solid forms, currently in form of its precursor 1, 3 , 5-trioxane of formula II
  • the fuming sulfuric acid which represents the reaction medium, also is the dehydrating agent which allows the direct transformation, in situ, of the 2-hydroxymethylterephthalic acid thus obtained of formula III
  • terephthalic acid is added to fuming sulfuric acid, currently containing at least by weight 20%, advantageously 22 ⁇ 33%, preferably 25 ⁇ 30% by weight of S ⁇ 3 , then the mixture thus obtained is treated with 1, 3 , 5-trioxane at a temperature of 30 ⁇ 35°C and subsequently heated at a temperature of 120 ⁇ 145°C, preferably at 130 ⁇ 135°C.
  • the temperature is brought to 130 ⁇ 145°C and, after a 2 ⁇ 5-hour heating at this temperature, there is formed compound III which concurrently dehydrates to give 5-carboxyphthalide.
  • the preferably used amount of fuming sulfuric acid containing 25 ⁇ 30% by weight in S0 3 is 2 ⁇ 8 1/Kg of terephthalic acid, advantageously 2 ⁇ 6 1/Kg, preferably 3 ⁇ 6 1/Kg, particularly about 3 1/kg.
  • the mixture when the reaction is over, the mixture may be poured into ice, by anyhow controlling the exothermia of this operation, and the strong acidity of the medium may be neutralized with a base, preferably sodium, hydroxide, carbonate or bicarbonate .
  • a base preferably sodium, hydroxide, carbonate or bicarbonate .
  • the mixture in sulfuric acid may also at first be diluted with glacial acetic acid and then treated with water.
  • the mixture is diluted with glacial acetic acid in an amount of 200 ml per 100 g of terephthalic acid, by letting the temperature to rise to 20 ⁇ 25°C at the end of the addition. Successively the water is added and, under external cooling, the temperature may rise to 45 °C. Finally, the mixture is neutralized with a base, as set forth above.
  • the isolation steps during the addition of the base, it may be suitable to reach a pH ⁇ 8, whereby the 5-carboxyphthalide is present in the solution as a salt, advantageously of an alkali metal, preferably of sodium, and to filter off the insoluble products whilst the 5-carboxyphthalide salt remains dissolved in the medium.
  • a neutral filter aid for example Celite" or Dicalite ® .
  • the 5- carboxyphthalide free acid may be easily recovered in good yields from the solution containing its salt by neutralization with an acid, for example with hydrochloric acid, and isolated in sufficiently pure form for its use as intermediate for the preparation of drugs.
  • the 5-carboxyphthalide precipitates at acid pH at a value of about 3, preferably in the range of 1.8 ⁇ 3.0, and is isolated by simple filtration.
  • the isolation steps through the salt preferably with an alkaline metal, it is suitable to maintain the pH value not higher than 8 in order to avoid the formation of by-products.
  • the alkaline agent it is suitable to control the pH changes when a value of about 5 is reached, because around this value it is possible that small additions of base involve considerable pH variations .
  • the mixture may be treated by dropping water thereinto, so that said water initially destroys any possible residual S0 3 and then dilutes sulfuric acid progressively thus rendering the isolation of 5-carboxyphthalide easier.
  • the addition of water, which produces exothermia, is preferably made at a temperature of 0 ⁇ 5°C.
  • the control of the temperature may be limited to the initial period of the addition of 10 ⁇ 15% of water (in respect of the used fuming sulfuric acid); afterwards, particular care are not necessary because the temperature of the mixture remains at about 20 ⁇ 25°C and, hence, it may be easily controlled.
  • the 5-carboxy phthalide may be isolated by simple filtration, by washing with water, if necessary by triturating the obtained product in water.
  • the mixture is heated to 120°C and it is noted that, already at
  • the solid is removed by filtration on Dicalite in a buchner and washed with water.
  • the solid is filtered, washed 3 times with 500 ml of deionized water at 40°C and suspended in 1000 ml of deionized water.
  • the suspension is heated under stirring at 50 ⁇ 55°C and kept 1 hour under these conditions, then it is hot filtered.
  • the solid is washed with deionized water and dried in vacuo at 50 °C to constant weight.
  • 180 g of light-brown coloured 5- carboxyphthalide with a purity (HPLC) > 95% are obtained.
  • the mixture is nevertheless heated to 130 ⁇ 135°C and kept 4 hours under these conditions.
  • the cooled mixture is poured, in about 1 hour and without exceeding the temperature of 25 ⁇ 35°C, into 3000 g of crushed ice.
  • 300 ml of 5% w/w solution of sodium hydroxide are added to the mixture to a pH __ 8.
  • the solid is
  • the mixture is let to stand 60 minutes under stirring at 20 ⁇ 25°C and filtered.
  • the wet product is suspended in 1900 ml of water.
  • the suspension is heated up to 25 ⁇ 30°C under stirring, its pH is adjusted to about 8 by gradual addition of 175 g of sodium bicarbonate.
  • the solid is filtered off
  • the mass is cooled to -5 ⁇ 0°C and 1800 ml of cold deionized water are added thereto. During this operation the temperature rises to 43 ⁇ 45°C. At the end of the addition, the mixture is kept 1 hour under stirring at 23 ⁇ 25°C, then it is filtered, the solid is washed with deionized water abundantly and suspended, still wet, in 1200 ml of deionized water at room temperature. To the suspension thus obtained, about 1550 g of a 7% solution of NaHC0 3 are added to a constant pH of 7,6 ⁇ 7,8.
  • the mixture is kept 1 hour under stirring at 20 ⁇ 25°C, the product thus obtained is filtered, still moist triturated in 300 ml of water repeatedly until the reddish colour of the mother liquors disappears. After the third trituration, the pH of the mother liquors stabilizes at values ranging from 5 to 6.
  • the product is dried in vacuo at 45 ⁇ 50°C until constant weight to give 47.5 g of 5-carboxyphthalide with a titer and a purity (HPLC) > 95%.
  • EXAMPLE 6 In a 3000-1 glass lined reactor, 550 Kg of oleum containing 25% of S0 3 are charged under vacuum and good aspiration, then, consecutively, under stirring, 56 Kg of terephthalic acid at 20 ⁇ 23°C and 26 Kg of 1 , 3 , 5-trioxane at 15 ⁇ 20°C are added thereinto. The reactor is heated at 130 ⁇ 133°C for 4 hours, then the mixture is cooled to 20 ⁇ 23°C and 118 Kg of glacial acetic acid are couled portionwise thereinto at a temperature not higher than 25 °C. At the end of this operation, 1000 Kg of water are added portionwise, whereby the temperature is maintained not higher than 43 ⁇ 45°C by circulation of water in the jacket.
  • the mixture is stirred for about 1 hour at 20 ⁇ 23°C, then the product is centrifugated, squeezed and abundantly washed with water in order to remove the larger amount of sulfuric acid from the mother liquors and to obtain 100 ⁇ 105 Kg of 5-carboxyphthalide as a well squeezed, wet raw-product.
  • the product thus obtained is suspended in 680 Kg of deionized water and a solution of 60 Kg of sodium bicarbonate in 540 Kg of deionized water is then slowly added to said suspension to a pH of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/EP2001/000617 2000-01-18 2001-01-17 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram Ceased WO2001053284A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU26798/01A AU779581B2 (en) 2000-01-18 2001-01-17 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram
PL01356563A PL356563A1 (en) 2000-01-18 2001-01-17 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram
HU0204187A HUP0204187A3 (en) 2000-01-18 2001-01-17 Process for the preparation of 1-oxo-1,3-dihydro-5-isobenzofurancarboxylic acid and its use for the production of citalopram
BR0107853-4A BR0107853A (pt) 2000-01-18 2001-01-17 Processo para a preparação de 5-carboxiftalida e seu uso para a produção de citalopram
EP01901181A EP1187822A1 (en) 2000-01-18 2001-01-17 Process for the preparation of 5-carboxphthalide and its use for the production of citalopram
ROA200200989A RO121737B1 (ro) 2000-01-18 2001-01-17 Procedeu de preparare a 5-carboxiftalidei şi utilizarea sa pentru producerea de citalopram
MXPA02007031A MXPA02007031A (es) 2000-01-18 2001-01-17 Proceso para la preparacion de 5-carboxiftaluro y su uso para la produccion de citalopram.
CA2397497A CA2397497C (en) 2000-01-18 2001-01-17 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram
BG106925A BG65763B1 (bg) 2000-01-18 2002-07-16 Метод за получаване на 5-карбоксифталид и неговото използване за получаване на циталопрам

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI000050A IT1317729B1 (it) 2000-01-18 2000-01-18 Procedimento per la preparazione della 5-carbossiftalide.
ITMI2000A000050 2000-01-18
US09/690,301 US6458973B1 (en) 2000-01-18 2000-10-17 Process for the preparation of 5-carboxyphthalide

Publications (1)

Publication Number Publication Date
WO2001053284A1 true WO2001053284A1 (en) 2001-07-26

Family

ID=26332721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/000617 Ceased WO2001053284A1 (en) 2000-01-18 2001-01-17 Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram

Country Status (21)

Country Link
US (4) US6458973B1 (https=)
EP (2) EP1118614B2 (https=)
JP (1) JP4558182B2 (https=)
CN (1) CN1184220C (https=)
AT (1) ATE219489T1 (https=)
AU (1) AU779581B2 (https=)
BG (1) BG65763B1 (https=)
BR (1) BR0107853A (https=)
CA (1) CA2397497C (https=)
DE (1) DE60000226T3 (https=)
DK (1) DK1118614T4 (https=)
ES (1) ES2178626T5 (https=)
HK (1) HK1042290B (https=)
HU (1) HUP0204187A3 (https=)
IT (1) IT1317729B1 (https=)
MX (1) MXPA02007031A (https=)
PL (1) PL356563A1 (https=)
PT (1) PT1118614E (https=)
RO (1) RO121737B1 (https=)
WO (1) WO2001053284A1 (https=)
ZA (1) ZA200205475B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR026063A1 (es) * 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
CN1427835A (zh) * 2000-03-13 2003-07-02 H·隆德贝克有限公司 5-取代的1-(4-氟苯基)-1,3-二氢异苯并呋喃的分步烷基化
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
US7687645B2 (en) * 2003-03-21 2010-03-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
CN100569765C (zh) 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
WO2006090409A1 (en) * 2005-02-28 2006-08-31 Kekule Pharma Ltd., An improved process for the preparation of 5 - carboxyphthalide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3607884A (en) * 1969-03-11 1971-09-21 Mobil Oil Corp Preparation of 5-carboxyphthalide in liquid sodium trioxide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976751A (en) 1974-10-21 1976-08-24 Allied Chemical Corporation Stabilization of liquid sulfur trioxide
DE2630927A1 (de) 1976-07-09 1978-01-19 Basf Ag Verfahren zur herstellung von phthalidcarbonsaeure-(5)
DE3605716A1 (de) 1986-02-22 1987-09-03 Henkel Kgaa Verwendung von unloeslichen schmutzsammlern zur regenerierung von wasch- und reinigungsloesungen
WO1998019513A2 (en) * 1997-07-08 1998-05-14 H. Lundbeck A/S Method for the preparation of citalopram
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AR026063A1 (es) * 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
AU1130901A (en) 1999-11-01 2001-05-14 H. Lundbeck A/S Method for the preparation of 5-carboxyphthalide
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3607884A (en) * 1969-03-11 1971-09-21 Mobil Oil Corp Preparation of 5-carboxyphthalide in liquid sodium trioxide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIGLER A J ET AL: "QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA,EDITIONS SCIENTIFIQUE ELSEVIER, PARIS,FR, vol. 12, no. 3, May 1977 (1977-05-01), pages 289 - 295, XP000944915, ISSN: 0223-5234 *
FORNEY, LEROY S. ET AL: "Reaction of formaldehyde with deactivated benzoic acids. An ester-directed electrophilic aromatic substitution process", J. ORG. CHEM. (1971), 36(5), 689-93, XP002145376 *
FORNEY, LEROY S.: "Reaction of terephthalic acid with formaldehyde in sulfur trioxide media", J. ORG. CHEM. (1970), 35(5), 1695-6, XP002145377 *

Also Published As

Publication number Publication date
HUP0204187A3 (en) 2005-05-30
ES2178626T3 (es) 2003-01-01
ES2178626T5 (es) 2011-06-02
DE60000226T3 (de) 2012-02-16
US6703516B2 (en) 2004-03-09
MXPA02007031A (es) 2004-09-06
AU2679801A (en) 2001-07-31
JP4558182B2 (ja) 2010-10-06
BG106925A (bg) 2004-01-30
JP2001206881A (ja) 2001-07-31
DK1118614T3 (da) 2002-10-14
HK1042290A1 (en) 2002-08-09
AU779581B2 (en) 2005-01-27
ZA200205475B (en) 2003-12-31
DE60000226D1 (de) 2002-07-25
EP1118614A2 (en) 2001-07-25
CA2397497C (en) 2010-07-06
IT1317729B1 (it) 2003-07-15
EP1187822A1 (en) 2002-03-20
EP1118614B1 (en) 2002-06-19
ATE219489T1 (de) 2002-07-15
BR0107853A (pt) 2002-10-29
DK1118614T4 (da) 2011-06-27
DE60000226T2 (de) 2003-03-06
ITMI20000050A0 (it) 2000-01-18
US20080249319A1 (en) 2008-10-09
US20040171851A1 (en) 2004-09-02
US20030009038A1 (en) 2003-01-09
PT1118614E (pt) 2002-11-29
ITMI20000050A1 (it) 2001-07-18
CN1406236A (zh) 2003-03-26
EP1118614A3 (en) 2001-10-24
HUP0204187A2 (hu) 2003-03-28
HK1042290B (en) 2003-07-18
EP1118614B2 (en) 2011-03-09
US6458973B1 (en) 2002-10-01
CA2397497A1 (en) 2001-07-26
RO121737B1 (ro) 2008-03-28
BG65763B1 (bg) 2009-10-30
CN1184220C (zh) 2005-01-12
PL356563A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
US20080249319A1 (en) Process for the preparation of 5-Carboxyphthalide
NO177142B (no) Fremgangsmåte for fremstilling av höyrent 2-fenyl-1,2-benzisoselenazol-3(2H)-on (ebselen)
US6008381A (en) Process for preparing 3-isochromanone
EP0669310B1 (en) Processes for producing tetrafluorophthalic anhydride
EP0359438B1 (en) Pyridazinone manufacture
KR100730623B1 (ko) 5-카복시프탈리드의 제조방법 및 시탈로프람의 생성을위한 그것의 사용
CN101506141A (zh) 2-(4-甲氧基羰基甲基苯氧基甲基)苯甲酸甲酯及其制造方法
US4264500A (en) Process of making 6-chloro-α-methyl-carbazole-2-acetic acid
RU2227137C2 (ru) СПОСОБ ПОЛУЧЕНИЯ α, α-ДИМЕТИЛФЕНИЛУКСУСНОЙ КИСЛОТЫ ИЗ α, α-ДИМЕТИЛБЕНЗИЛЦИАНИДА БЕЗ ДАВЛЕНИЯ
US4127607A (en) Process for the preparation of an acetamide derivative
RU1811529C (ru) Способ получени 3-изопропил-бензо-2-тио-1,3-диазинон-(4)-2,2-диоксида
JP3105367B2 (ja) 4−(1−イミダゾリルメチル)ケイ皮酸の製造方法
RU2098412C1 (ru) Способ получения гидрохлорида этилового эфира 10-(3-диэтиламинопропионил)фенотиазинкарбаминовой-2 кислоты
RU2053217C1 (ru) Способ получения 5-хлорсалициловой кислоты
JPH07196610A (ja) 5−クロロ−2−オキシンドールの製造法
KR100898099B1 (ko) 잘토프로펜의 제조방법
SU1721051A1 (ru) Способ получени 2-галоидпроизводных фурана
JPS6011022B2 (ja) 1−(3,5−ジメトキシ−4−ヒドロキシ)フエニル−2−(n−メチル)アミノ−エタノ−ルの塩酸塩の製造法
JPH03275641A (ja) ヒドロキシビフェニル化合物及びその製造法
JP2001512467A (ja) 3−[2−クロロ−4−(トリフルオロメチル)フェノキシ]安息香酸の単離方法
MXPA01002614A (en) METHOD FOR PRESSURELESS PRODUCTION OF&agr;,&agr;-DIMETHYLPHENYL ACETIC ACID FROM&agr;,&agr;-DIMETHYL BENZYL CYANIDE
HU180688B (hu) Módosított eljárás 6-fenil-acetamido-2,2-dimetil- -penam - 3-karbonsav-2- (dimetil- amino) - etil - észter- - hidrojodid előállítására

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2001901181

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2002 200200989

Country of ref document: RO

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001901181

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 26798/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/905/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2397497

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 106925

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007031

Country of ref document: MX

Ref document number: 1020027009223

Country of ref document: KR

Ref document number: 018038484

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027009223

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 26798/01

Country of ref document: AU